NASDAQ:BCRX

Biocryst Pharmaceuticals Stock Insider Trading

Healthcare > Biotechnology

Buy BCRX

*Your capital is at risk

$8.25

-0.0900 (-1.08%)

At Close: Jun 03, 2026

BioCryst Pharmaceuticals Stock Insider Power

Based on the 100 latest insides trades, we have calculated the insider power to be negative at -8.99. In total, the insiders bought 6.54M and sold 1.09M BCRX shares in the last 100 trades. The insider score can be negative despite buy/sell ratio being positive. The score focuses on the quality of the trades.

Insider Power (Last 100 transactions)	-8.99
● Buy	6.54M shares
● Sell	1.09M shares
80% Buy Activity Negligible or No Correlation
Sell Signal Low Confidence May 13, 2026 Analysis Breakdown: Confidence increased due to high data reliability score of 100.

Historical Insider Trades

Date	Type	Person	Role	Amount
Dec 17, 2026 Buy	Emp. Stock Option (Right to Buy)	Dullinger Ronald Chief Commercial Officer	Officer	255 050 Value: $1.82M
May 29, 2026 Buy	Common Stock A-Award	Milne Jill C. Director	Director	1 262 Value: $11.2K
May 29, 2026 Buy	Common Stock A-Award	Stonehouse Jon P Director	Director	631 Value: $6K
May 29, 2026 Buy	Common Stock A-Award	Mckee Amy E Director	Director	631 Value: $6K
May 29, 2026 Buy	Common Stock A-Award	Milano Vincent Director	Director	1 122 Value: $10K
May 29, 2026 Buy	Common Stock A-Award	Frank Steven Director	Director	1 262 Value: $11.2K
May 18, 2026 Sell	Common Stock S-Sale	Mckee Amy E Director	Director	11 180 Value: $100.3K
May 13, 2026 Buy	Emp. Stock Option (Right to Buy) M-Exempt	Barnes Alane P Chief Legal Officer	Officer	62 500 Value: $315.0K
May 13, 2026 Sell	Common Stock S-Sale	Barnes Alane P Chief Legal Officer	Officer	62 500 Value: $596.3K
May 13, 2026 Buy	Common Stock M-Exempt	Barnes Alane P Chief Legal Officer	Officer	62 500 Value: $315.0K
Apr 06, 2026 Buy	Common Stock J-Other	Menon Sandeep Officer	Officer	0 Value: $0
Apr 06, 2026 Buy	Common Stock A-Award	Menon Sandeep Chief R&d Officer	Officer	205 150 Value: $1.94M
Apr 06, 2026 Buy	Emp. Stock Option (Right to Buy) A-Award	Menon Sandeep Chief R&d Officer	Officer	441 350 Value: $4.18M
Mar 20, 2026 Buy	Automatic Stock Option Grant M-Exempt	Heggie Theresa Director	Director	49 933 Value: $314.6K
Mar 20, 2026 Sell	Common Stock S-Sale	Heggie Theresa Director	Director	49 933 Value: $504.8K
Mar 20, 2026 Buy	Common Stock M-Exempt	Heggie Theresa Director	Director	49 933 Value: $314.6K
Mar 16, 2026 Buy	Emp. Stock Option (Right to Buy) M-Exempt	Barnes Alane P Chief Legal Officer	Officer	150 000 Value: $826.5K
Mar 16, 2026 Sell	Common Stock S-Sale	Barnes Alane P Chief Legal Officer	Officer	150 000 Value: $1.37M
Mar 16, 2026 Buy	Common Stock M-Exempt	Barnes Alane P Chief Legal Officer	Officer	150 000 Value: $826.5K
Mar 02, 2026 Buy	Emp. Stock Option (Right to Buy) M-Exempt	Stonehouse Jon P Director	Director	305 995 Value: $985.3K
Mar 02, 2026 Buy	Common Stock M-Exempt	Stonehouse Jon P Director	Director	305 995 Value: $985.3K
Mar 02, 2026 Sell	Common Stock D-Return	Stonehouse Jon P Director	Director	305 995 Value: $2.64M
Feb 27, 2026 Buy	Common Stock A-Award	Mckee Amy E Director	Director	642 Value: $6K
Feb 27, 2026 Buy	Common Stock A-Award	Frank Steven Director	Director	1 285 Value: $11.2K
Feb 27, 2026 Buy	Common Stock A-Award	Milano Vincent Director	Director	848 Value: $7K

About Insider Power

Insider Power is a proprietary algorithm developed by StockInvest.us to evaluate the significance of insider transactions. The calculation considers the size, type, and timing of transactions, as well as the insider’s role within the company.

It is important to note that, in general, there is little to no correlation between insider transactions and short-term stock price movements. In one of our studies, only 0.22%^* of stocks with insider activity showed a measurable correlation — and even then, it was unclear whether the effect was caused by insider actions or simply by the stock’s broader trend.

While our algorithms are designed to highlight potentially meaningful signals, these cannot be regarded as statistically significant on their own. Insider trading activity should therefore be seen as informative rather than as direct trading guidance. The Insider Power metric was created to present this information in a clearer and more accessible way, helping investors better understand the possible context of insider activity.

* October 6th, 2025 - Tested on 5562 stocks

ABOUT BIOCRYST PHARMACEUTICALS

BioCryst Pharmaceuticals, Inc., a biotechnology company, discovers novel, oral, and small-molecule medicines. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat hereditary angioedema. It is also developing BCX9930, an oral factor D inhibitor, which is in Phase II...

Read Full Profile Here